Sagent Pharmaceuticals' Clindamycin Phosphate ANDA090108 Receives AP Status
Sagent Pharmaceuticals has received an Abbreviated New Drug Application (ANDA) approval status for Clindamycin Phosphate.
Asset / Drug
Drug and asset intelligence for Sagent with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.